BOULDER, Colo., Oct. 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, October 30, 2018. Ron Squarer, Chief Executive Officer, will lead the call.
Tuesday, October 30, 2018
9:00 a.m. Eastern Time
Webcast, including Replay and Conference Call Slides:
About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), larotrectinib and LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Ganovo® (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2019-on-october-30-2018-300735608.html